Literature DB >> 12649720

Influence of hepatitis C virus coinfection on failure of HIV-infected patients receiving highly active antiretroviral therapy to achieve normal serum beta2microglobulin levels.

J A García-García1, J A Mira, J Fernández-Rivera, A J Ramos, J Vargas, J Macías, J A Pineda.   

Abstract

The influence of hepatitis C virus (HCV) coinfection on the kinetics of serum beta2microglobulin levels in HIV-infected patients undergoing highly active antiretroviral therapy was analyzed. After 96 weeks of therapy, beta2microglobulin levels declined significantly both in 24 HCV seronegative and 16 HCV-infected individuals. Throughout the follow-up period, HCV-infected patients showed higher beta2microglobulin values than non-HCV-infected patients. These results show that HCV infection precludes immune deactivation in HIV-infected patients undergoing highly active antiretroviral therapy.

Entities:  

Mesh：

Substances：

Year:  2003        PMID： 12649720     DOI： 10.1007/s10096-003-0888-4

Source DB:  PubMed          Journal:  Eur J Clin Microbiol Infect Dis        ISSN： 0934-9723            Impact factor:   3.267


  14 in total

1.  Soluble beta2-mu-associated and beta2-mu-free HLA class I heavy chain serum levels in interferon-alpha nonresponder chronic hepatitis C patients. Markers of immune activation, and response to antiviral retreatment.

Authors:  F Puppo; F Torre; P Contini; M Ghio; S Brenci; R Brizzolara; N Sinelli; N Campo; F Indiveri; A Picciotto
Journal:  J Clin Immunol       Date:  2000-11       Impact factor: 8.317

2.  Advanced glycation end product (AGE): characterization of the products from the reaction between D-glucose and serum albumin.

Authors:  J T Wu; M C Tu; P Zhung
Journal:  J Clin Lab Anal       Date:  1996       Impact factor: 2.352

3.  Reduction of immune system activation in HIV-1-infected patients undergoing highly active antiretroviral therapy.

Authors:  J M Franco; A Rubio; C Rey; M Leal; J Macías; J A Pineda; B Sánchez; A Sánchez-Quijano; A Nuñez-Roldán; E Lissen
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1999-10       Impact factor: 3.267

Review 4.  The immunopathogenesis of human immunodeficiency virus infection.

Authors:  G Pantaleo; C Graziosi; A S Fauci
Journal:  N Engl J Med       Date:  1993-02-04       Impact factor: 91.245

5.  Usefulness of route of transmission, absolute CD8+ T-cell counts, and levels of serum tumor necrosis factor alpha as predictors of survival of HIV-1-infected patients with very low CD4 + T-cell counts.

Authors:  J Macías; M Leal; J Delgado; J A Pineda; J Muñoz; F Relimpio; A Rubio; C Rey; E Lissen
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2001-04       Impact factor: 3.267

6.  Predicting clinical progression or death in subjects with early-stage human immunodeficiency virus (HIV) infection: a comparative analysis of quantification of HIV RNA, soluble tumor necrosis factor type II receptors, neopterin, and beta2-microglobulin. Multicenter AIDS Cohort Study.

Authors:  D S Stein; R H Lyles; N M Graham; C J Tassoni; J B Margolick; J P Phair; C Rinaldo; R Detels; A Saah; J Bilello
Journal:  J Infect Dis       Date:  1997-11       Impact factor: 5.226

7.  Serum beta2-microglobulin in chronic hepatitis C.

Authors:  M Malaguarnera; S Restuccia; I Di Fazio; A M Zoccolo; B A Trovato; G Pistone
Journal:  Dig Dis Sci       Date:  1997-04       Impact factor: 3.199

Review 8.  Host factors and the pathogenesis of HIV-induced disease.

Authors:  A S Fauci
Journal:  Nature       Date:  1996-12-12       Impact factor: 49.962

9.  Serum beta 2-microglobulin and prediction of progression to AIDS in HIV infection.

Authors:  A R Lifson; N A Hessol; S P Buchbinder; P M O'Malley; L Barnhart; M Segal; M H Katz; S D Holmberg
Journal:  Lancet       Date:  1992-06-13       Impact factor: 79.321

10.  Serum levels of tumor necrosis factor-alpha (TNF alpha) and soluble TNF receptors in human immunodeficiency virus type 1 infection--correlations to clinical, immunologic, and virologic parameters.

Authors:  P Aukrust; N B Liabakk; F Müller; E Lien; T Espevik; S S Frøland
Journal:  J Infect Dis       Date:  1994-02       Impact factor: 5.226
View more
  3 in total

1.  Impaired recovery of CD4+ cell counts following highly active antiretroviral therapy in drug-naïve patients coinfected with human immunodeficiency virus and hepatitis C virus.

Authors:  J Macías; J A Pineda; F Lozano; J E Corzo; A Ramos; E León; J A García-García; J Fernández-Rivera; J A Mira; J Gómez-Mateos
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2003-10-23       Impact factor: 3.267

Review 2.  Molecular and contextual markers of hepatitis C virus and drug abuse.

Authors:  Paul Shapshak; Charurut Somboonwit; Lydia N Drumright; Simon D W Frost; Deborah Commins; Timothy L Tellinghuisen; William K Scott; Robert Duncan; Clyde McCoy; J Bryan Page; Brian Giunta; Francisco Fernandez; Elyse Singer; Andrew Levine; Alireza Minagar; Oluwadayo Oluwadara; Taiwo Kotila; Francesco Chiappelli; John T Sinnott
Journal:  Mol Diagn Ther       Date:  2009       Impact factor: 4.074

3.  Elevated serum β2-microglobulin in individuals coinfected with hepatitis B and hepatitis D virus in a rural settings in Southwest Nigeria.

Authors:  Lawrence Ehis Okoror; Ayodele Oluwaseun Ajayi; Oluwaseun Benjamin Ijalana
Journal:  BMC Res Notes       Date:  2017-12-08
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.